Diamyd falls on diabetes miss

Diamyd Medical AB (SSE:DIAM B) fell SEK105 (85%) to SEK18 on Monday after reporting that Diamyd missed the primary endpoint of preserving beta cell function as measured by meal-stimulated C-peptide levels vs. placebo at 15 months in a Phase III trial to treat Type I diabetes. The double-blind, European Phase III trial enrolled more than 320 patients ages 10-20 with newly diagnosed Type I diabetes. Data will be presented at the American Diabetes Association meeting in San Diego in June. Diamyd is a recombinant human glutamic acid decarboxylase (GAD) 65 subcutaneous vaccine. ...